NYSE:GMED • US3795772082
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GLOBUS MEDICAL INC - A (GMED).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-25 | Needham | Maintains | Buy -> Buy |
| 2026-02-25 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-30 | Needham | Upgrade | Hold -> Buy |
| 2026-01-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-12-17 | Freedom Capital Markets | Initiate | Hold |
| 2025-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-18 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-11-10 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-07 | Truist Securities | Upgrade | Hold -> Buy |
| 2025-11-07 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-10-28 | Stifel | Reiterate | Hold |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-22 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-21 | Needham | Reiterate | Hold -> Hold |
| 2025-07-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-27 | BTIG | Downgrade | Buy -> Neutral |
| 2025-05-27 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-05-12 | Truist Securities | Maintains | Hold -> Hold |
| 2025-05-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.568B 53.35% | 2.519B 60.62% | 2.939B 16.65% | 3.266B 11.13% | 3.471B 6.28% | 3.722B 7.23% | 3.994B 7.31% | 4.242B 6.21% | |
| EBITDA YoY % growth | 346.583M 13.78% | 479.63M 38.39% | 814.556M 69.83% | 1.053B 29.27% | 1.15B 9.21% | 1.242B 8.00% | 1.504B 21.10% | 1.627B 8.18% | |
| EBIT YoY % growth | 201.85M -14.58% | 225.606M 11.77% | 537.714M 138.34% | 796.81M 48.18% | 892.42M 12.00% | 978.64M 9.66% | N/A | N/A | |
| Operating Margin | 12.87% | 8.95% | 18.30% | 24.40% | 25.71% | 26.29% | N/A | N/A | |
| EPS YoY % growth | 2.33 12.56% | 3.14 34.76% | 4.00 27.39% | 4.52 12.98% | 5.00 10.71% | 5.52 10.41% | 6.35 15.04% | 6.92 8.83% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.94 37.96% | 1.08 25.46% | 1.19 0.61% | 1.35 5.53% | 1.13 20.91% | 1.21 12.45% | 1.27 6.84% | 1.43 5.59% |
| Revenue Q2Q % growth | 751.74M 25.68% | 809.39M 8.59% | 821.73M 6.85% | 883.16M 6.87% | 792.78M 5.46% | 858.8M 6.10% | 877.91M 6.84% | 940.15M 6.45% |
| EBITDA Q2Q % growth | 228.88M 39.32% | 256.66M -1.24% | 274.27M -20.00% | 306.34M -33.14% | 253.64M 10.82% | 277.42M 8.09% | 297.09M 8.32% | 333.7M 8.93% |
| EBIT Q2Q % growth | 166.46M 69.49% | 188.74M 53.23% | 210.26M 55.73% | 242.08M 33.52% | 175.66M 5.53% | 199.39M 5.64% | 215.41M 2.45% | 249.48M 3.06% |
All data in USD
22 analysts have analysed GMED and the average price target is 108.12 USD. This implies a price increase of 29.05% is expected in the next year compared to the current price of 83.78.
GLOBUS MEDICAL INC - A (GMED) will report earnings on 2026-05-01.
The consensus EPS estimate for the next earnings of GLOBUS MEDICAL INC - A (GMED) is 0.94 USD and the consensus revenue estimate is 751.74M USD.
The expected long term growth rate for GLOBUS MEDICAL INC - A (GMED) is 7.79%.